These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37575772)

  • 21. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Muller O; Moarof I; Siontis GCM; Cook S; Weilenmann D; Kaiser C; Cuculi F; Hunziker L; Eberli FR; Jüni P; Windecker S
    Lancet; 2018 Sep; 392(10149):737-746. PubMed ID: 30170848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
    Pilgrim T; Heg D; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Fahrni T; Moschovitis A; Noble S; Eberli FR; Wenaweser P; Jüni P; Windecker S
    Lancet; 2014 Dec; 384(9960):2111-22. PubMed ID: 25189359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months' results from the S-FLEX UK registry.
    Choudhury A; Garg S; Smith J; Sharp A; Nabais de Araujo S; Chauhan A; Patel N; Wrigley B; Chattopadhyay S; Zaman AG
    BMJ Open; 2019 Oct; 9(10):e026578. PubMed ID: 31604782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients.
    Sinha SK; Aggarwal P; Pandey U; Razi M; Kumar A; Krishna V
    Anatol J Cardiol; 2021 Feb; 25(2):111-119. PubMed ID: 33583818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial.
    Iglesias JF; Heg D; Roffi M; Tüller D; Noble S; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Häner J; Jüni P; Windecker S; Pilgrim T
    Circ Cardiovasc Interv; 2019 Aug; 12(8):e008024. PubMed ID: 31525083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of target lesion failure after treatment of left main, bifurcation, or chronic total occlusion lesions with ultrathin-strut drug-eluting coronary stents in the ULTRA registry.
    de Filippo O; Bruno F; Pinxterhuis TH; Gąsior M; Perl L; Gaido L; Tuttolomondo D; Greco A; Verardi R; Lo Martire G; Iannaccone M; Leone A; Liccardo G; Caglioni S; González Ferreiro R; Rodinò G; Musumeci G; Patti G; Borzillo I; Tarantini G; Wańha W; Casella B; Ploumen EH; Pyka Ł; Kornowski R; Gagnor A; Piccolo R; Roubin SR; Capodanno D; Zocca P; Conrotto F; De Ferrari GM; von Birgelen C; D'Ascenzo F;
    Catheter Cardiovasc Interv; 2023 Aug; 102(2):221-232. PubMed ID: 37232278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
    Pilgrim T; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Losdat S; Eeckhout E; Valgimigli M; Jüni P; Windecker S; Iglesias JF
    JACC Cardiovasc Interv; 2021 Mar; 14(6):639-648. PubMed ID: 33727005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents.
    Chandrasekhar J; Kok MM; Kalkman DN; Aquino MB; Zocca P; Woudstra P; Beijk MA; Kerkmeijer LS; Sartori S; Baber U; Tijssen JG; Koch KT; Dangas GD; Colombo A; Pocock S; von Birgelen C; Mehran R; de Winter RJ;
    JACC Cardiovasc Interv; 2020 Apr; 13(7):820-830. PubMed ID: 32273094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    von Birgelen C; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man FHAF; Louwerenburg JHW; Hartmann M; Zocca P; Linssen GCM; van der Palen J; Doggen CJM; Löwik MM
    Lancet; 2016 Nov; 388(10060):2607-2617. PubMed ID: 27806902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The BIOFLOW-III Italian Satellite Registry: 18-month results of the Orsiro stent in an all-comer high-risk population.
    Bartorelli AL; Versaci F; Briguori C; Tomai F; Aprigliano G; Poli A; Vigna C; Marinucci L; My L; Masi F; Turturo M
    J Cardiovasc Med (Hagerstown); 2019 Jul; 20(7):464-470. PubMed ID: 30994511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.
    Jensen LO; Thayssen P; Maeng M; Ravkilde J; Krusell LR; Raungaard B; Junker A; Terkelsen CJ; Veien KT; Villadsen AB; Kaltoft A; Tilsted HH; Hansen KN; Aaroe J; Kristensen SD; Hansen HS; Jensen SE; Madsen M; Bøtker HE; Berencsi K; Lassen JF; Christiansen EH
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions.
    Dan K; Garcia-Garcia HM; Kolm P; Windecker S; Saito S; Kandzari DE; Waksman R
    Circ Cardiovasc Interv; 2020 Sep; 13(9):e009189. PubMed ID: 32895004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
    Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Baldetti L; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Reimers B; Fabbiocchi F; Bartorelli A; Colombo A; Godino C
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):255-265. PubMed ID: 31905259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of patients treated with ultrathin-strut biodegradable polymer sirolimus-eluting stents versus fluoropolymer-based everolimus-eluting stents: a meta-analysis of randomised trials.
    Cassese S; Ndrepepa G; Byrne RA; Kufner S; Lahmann AL; Mankerious N; Xhepa E; Laugwitz KL; Schunkert H; Fusaro M; Kastrati A; Joner M
    EuroIntervention; 2018 Jun; 14(2):224-231. PubMed ID: 29537375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
    Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Clinical Outcomes Following Single versus Multivessel Percutaneous Coronary Intervention Using Biodegradable Polymer Coated Sirolimus-Eluting Stent in an All-comers Patient Population.
    Chandwani P; Verma P; Saxena S; Ramachandran PK; Abhyankar A; Sandhu MS; Parikh N; Bhupali A; Jain S; Prajapati J
    Cardiovasc Hematol Agents Med Chem; 2016; 14(1):39-48. PubMed ID: 26585397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus.
    Waksman R; Shlofmitz E; Windecker S; Koolen JJ; Saito S; Kandzari D; Kolm P; Lipinski MJ; Torguson R
    Am J Cardiol; 2019 Oct; 124(7):1020-1026. PubMed ID: 31353004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration.
    de Winter RJ; Chandrasekhar J; Kalkman DN; Aquino MB; Woudstra P; Beijk MA; Sartori S; Baber U; Tijssen JG; Koch KT; Dangas GD; Colombo A; Mehran R; ;
    JACC Cardiovasc Interv; 2018 Oct; 11(19):1969-1978. PubMed ID: 30286855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial.
    Iñiguez A; Chevalier B; Richardt G; Neylon A; Jiménez VA; Kornowski R; Carrie D; Moreno R; Barbato E; Serra-Peñaranda A; Guiducci V; Valdés-Chávarri M; Yajima J; Wijns W; Saito S;
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):175-184. PubMed ID: 31033154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.